A detailed history of Vanguard Group Inc transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,635,520 shares of ATXS stock, worth $25.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,635,520
Previous 2,590,160 1.75%
Holding current value
$25.2 Million
Previous $23.6 Million 23.11%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$8.97 - $12.65 $406,879 - $573,804
45,360 Added 1.75%
2,635,520 $29 Million
Q2 2024

Aug 13, 2024

BUY
$8.83 - $13.51 $479,195 - $733,174
54,269 Added 2.14%
2,590,160 $23.6 Million
Q1 2024

May 10, 2024

BUY
$6.99 - $16.69 $3.36 Million - $8.01 Million
480,184 Added 23.36%
2,535,891 $35.7 Million
Q4 2023

Feb 14, 2024

BUY
$4.42 - $8.06 $2.41 Million - $4.4 Million
545,786 Added 36.15%
2,055,707 $15.8 Million
Q3 2023

Nov 14, 2023

BUY
$6.89 - $9.86 $20,015 - $28,643
2,905 Added 0.19%
1,509,921 $11.3 Million
Q2 2023

Aug 14, 2023

BUY
$8.33 - $13.72 $1.58 Million - $2.61 Million
190,163 Added 14.44%
1,507,016 $12.6 Million
Q1 2023

May 15, 2023

BUY
$11.2 - $15.79 $7.42 Million - $10.5 Million
662,527 Added 101.25%
1,316,853 $17.5 Million
Q4 2022

Feb 10, 2023

BUY
$7.44 - $14.89 $916,407 - $1.83 Million
123,173 Added 23.19%
654,326 $9.74 Million
Q3 2022

Nov 14, 2022

BUY
$2.97 - $10.34 $82,396 - $286,862
27,743 Added 5.51%
531,153 $4.8 Million
Q2 2022

Aug 12, 2022

SELL
$2.46 - $6.96 $71,728 - $202,939
-29,158 Reduced 5.47%
503,410 $1.51 Million
Q4 2021

Feb 14, 2022

SELL
$5.08 - $8.62 $108,356 - $183,864
-21,330 Reduced 3.85%
532,568 $2.87 Million
Q3 2021

Nov 12, 2021

BUY
$7.32 - $12.9 $4.05 Million - $7.15 Million
553,898 New
553,898 $4.9 Million

Others Institutions Holding ATXS

About Astria Therapeutics, Inc.


  • Ticker ATXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,178,000
  • Market Cap $145M
  • Description
  • Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...
More about ATXS
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.